Insider Buying: Aerie Pharmaceuticals Inc (NASDAQ:AERI) Major Shareholder Buys 1,153 Shares of Stock

Aerie Pharmaceuticals Inc (NASDAQ:AERI) major shareholder Foresite Capital Management Ii acquired 1,153 shares of Aerie Pharmaceuticals stock in a transaction on Wednesday, August 21st. The shares were bought at an average price of $23.25 per share, for a total transaction of $26,807.25. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Foresite Capital Management Ii also recently made the following trade(s):

  • On Monday, August 19th, Foresite Capital Management Ii acquired 3,847 shares of Aerie Pharmaceuticals stock. The shares were bought at an average price of $23.34 per share, for a total transaction of $89,788.98.
  • On Friday, August 16th, Foresite Capital Management Ii acquired 100,000 shares of Aerie Pharmaceuticals stock. The shares were bought at an average price of $24.23 per share, for a total transaction of $2,423,000.00.
  • On Wednesday, August 14th, Foresite Capital Management Ii acquired 100,000 shares of Aerie Pharmaceuticals stock. The shares were bought at an average price of $23.73 per share, for a total transaction of $2,373,000.00.
  • On Monday, August 12th, Foresite Capital Management Ii acquired 189,555 shares of Aerie Pharmaceuticals stock. The shares were bought at an average price of $24.43 per share, for a total transaction of $4,630,828.65.

Shares of NASDAQ:AERI traded down $0.55 during trading on Friday, hitting $23.42. The company’s stock had a trading volume of 516,667 shares, compared to its average volume of 1,026,227. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.52. Aerie Pharmaceuticals Inc has a fifty-two week low of $20.72 and a fifty-two week high of $64.25. The stock’s 50-day moving average price is $23.61 and its two-hundred day moving average price is $36.25. The company has a market capitalization of $1.12 billion, a PE ratio of -5.04 and a beta of 0.41.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.80) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.07. Aerie Pharmaceuticals had a negative return on equity of 89.52% and a negative net margin of 478.81%. The business had revenue of $15.84 million for the quarter, compared to analysts’ expectations of $14.60 million. On average, equities analysts predict that Aerie Pharmaceuticals Inc will post -3.48 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in AERI. BlackRock Inc. lifted its stake in shares of Aerie Pharmaceuticals by 11.0% in the second quarter. BlackRock Inc. now owns 3,358,901 shares of the company’s stock worth $99,255,000 after acquiring an additional 331,884 shares in the last quarter. C WorldWide Group Holding A S raised its stake in Aerie Pharmaceuticals by 235.0% during the second quarter. C WorldWide Group Holding A S now owns 456,142 shares of the company’s stock valued at $13,479,000 after buying an additional 320,000 shares in the last quarter. Norges Bank acquired a new stake in Aerie Pharmaceuticals during the fourth quarter valued at approximately $10,815,000. Granite Investment Partners LLC acquired a new stake in Aerie Pharmaceuticals during the first quarter valued at approximately $13,337,000. Finally, Pictet Asset Management Ltd. raised its stake in Aerie Pharmaceuticals by 42.2% during the first quarter. Pictet Asset Management Ltd. now owns 810,410 shares of the company’s stock valued at $38,494,000 after buying an additional 240,322 shares in the last quarter.

A number of brokerages have commented on AERI. Piper Jaffray Companies reduced their price objective on Aerie Pharmaceuticals from $76.00 to $53.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. JMP Securities reduced their price objective on Aerie Pharmaceuticals from $58.00 to $52.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 8th. Mizuho set a $63.00 price objective on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 16th. BidaskClub upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 13th. Finally, HC Wainwright restated a “buy” rating and set a $57.00 price objective on shares of Aerie Pharmaceuticals in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $61.00.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Read More: Understanding Compound Annual Growth Rate (CAGR)

Insider Buying and Selling by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.